Here are five things to know:
1. The brokers gave Mazor stock at 1.86 rating.
2. The seven brokers rate Mazor stock as “buy.”
3. There are three equities research analysts give the stock a “hold” and four with a “strong buy.”
4. The company’s rating score dropped 11.4 percent in 90 days.
5. The price target is $15.88, according to the brokers.
6. The brokers predict the company will post a $0.22 EPS for this quarter.
More articles on orthopedic devices:
Shoulder reconstruction device market to see rapid growth—With DePuy Synthes at the helm
New NuVasive CEO Gregory Lucier buys 34k shares—5 key notes
LESS Institute gets $30M senior credit facility—5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
